Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EDP-323 Dose Regimen 1 · 1 trial · 1 indication
Measured by qRT-PCR in nasal samples.
| Arm | Type | Description |
|---|---|---|
| EDP-323 Arm A | EXPERIMENTAL | Subjects will take EDP-323 Dose 1 orally for 5 days |
| EDP-323 Arm B | EXPERIMENTAL | Subjects will take EDP-323 Dose 2 orally for 5 days |
| Placebo Arm C | PLACEBO_COMPARATOR | Subjects will take matching placebo orally for 5 days |
| Name | Type | Description |
|---|---|---|
| EDP-323 Dose Regimen 1 | DRUG | EDP-323 capsule |
| EDP-323 Dose Regimen 2 | DRUG | EDP-323 capsule |
| Placebo | DRUG | Placebo capsule |
Inclusion Criteria: * An informed consent document signed and dated by the subject. * Age 18 to 55 years, inclusive. * In good health with no history of major medical conditions. * A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m2 and ≤ 35kg/m2. Exclusion Criteria: * Pregnant or nu...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
EDP-323 Dose Regimen 1 is being developed for the treatment of respiratory syncytial virus (RSV) infection. It is an investigational small molecule antiviral from Enanta Pharmaceuticals, studied in a controlled human viral challenge model rather than in naturally infected patients.
EDP-323 Dose Regimen 1 is being developed by Enanta Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker ENTA. Enanta is the sponsor of the clinical program evaluating this RSV antiviral candidate.
EDP-323 Dose Regimen 1 has completed a Phase 2a clinical trial. It is an investigational agent and has not been approved by the FDA or any other regulatory authority for the treatment of RSV infection.
EDP-323 Dose Regimen 1 was evaluated in a single completed Phase 2a trial, NCT06170242, titled a controlled Phase 2a study to evaluate the efficacy of EDP-323 against respiratory syncytial virus infection in a virus challenge model. The trial enrolled 142 participants in the United Kingdom.
NCT06170242 was a randomized, double-blind, placebo-controlled Phase 2a human viral challenge study. It enrolled 142 healthy adult volunteers aged 18 years and older of all sexes in the United Kingdom, and the trial has been completed.